3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Conditions
Neoplasms
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
1488
Cisplatin
1410
Paclitaxel
1316
Radiotherapy
1259
Carboplatin
1247
Gemcitabine
1214
Docetaxel
1110
Bevacizumab
1029
Fluorouracil
894
Doxorubicin
786
Dexamethasone
746
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
673
Etoposide
673
Irinotecan
634
Filgrastim
621
Cytarabine
584
Leucovorin
578
Nivolumab
557
Vincristine
510
Prednisone
474
Cetuximab
464
Bortezomib
457
Erlotinib Hydrochloride
456
Trastuzumab
448
Methotrexate
437
Lenalidomide
426
Pemetrexed
419
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
kalinox
×
Clear all
NCT03755895
2025-10-03
HYCUDES
Institut de Cancérologie de Lorraine
Phase 2
Completed
68 enrolled
NCT03483194
2020-06-23
REVEH
Weprom
Phase 2/3
Completed
126 enrolled